Recall Register

Device recall: RayStation 4.5, 4.7, 4.9, 5, 6, 7, 8A, 8B, 9A, 9B, 10A, 10B, RayPlan 1, 2, 7, 8A, 8B, 9A, 10A, 10B including some of…

Class II FDA enforcement event 87797. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

For some LINAC types, merging clinical beams with beams of approximate dose may lead to the approximate dose erroneously labeled as clinical dose. Merge beams can be used manually, in scripting, or as part of the Automated breast planning feature. In some cases, when merging two beams where the first beam has clinical dose and the second beam has approximate dose, the dose of the resulting beam…

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

RAYSEARCH LABORATORIES AB started this device recall on 22 Feb 2021. The firm address in the FDA record is in Stockholm. FDA put the recall in Class II. FDA event 87797 has 1 product record. The first FDA enforcement report date is 26 May 2021. The record gives the status Terminated, with the termination date 1 May 2023.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

US Nationwide distribution.

Recalling firm

RAYSEARCH LABORATORIES AB, Stockholm, N/A, Sweden.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 87797: product records
Recall numberProductQuantityClassStatusReport date
Z-1597-2021RayStation 4.5, 4.7, 4.9, 5, 6, 7, 8A, 8B, 9A, 9B, 10A, 10B, RayPlan 1, 2, 7, 8A, 8B, 9A, 10A, 10B including some of the Service Packs. Standalone software treatment planning system116 unitsClass IITerminated26 May 2021

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Device events that started in 2021
900
Share of these events in Class II
89%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
57

Other events of the firm

Official channels

Cite this page

Recall Register. FDA enforcement event 87797. https://recallregister.com/fda/ii/87797/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA device enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: US Nationwide distribution.
What quantity of product is in FDA event 87797?
The FDA record gives this quantity: 116 units
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many device recalls of 2021 have the same class?
89% of the 900 device events that started in 2021 are in Class II.